申请人:Bayer Aktiengesellschaft
公开号:US05096899A1
公开(公告)日:1992-03-17
Compounds of the structural formulae ##STR1## and their pharmaceutically acceptable salts, esters and amide derivatives, in which R.sup.1 and R.sup.2, independently of one another, denote hydrogen or pharmaceutically acceptable groups which have 1 to 10 carbon atoms and are bonded to the remaining part of the molecule via carbon-carbon single bonds, and in which R.sup.3, R.sup.4 and R.sup.5, independently of one another, denote pharmaceutically acceptable groups which have 1 to 10 carbon atoms and are bonded to the remaining part of the molecule via carbon-carbon single bonds, are useful antibiotics. The trisubstitution by three groups R.sup.3, R.sup.4 and R.sup.5, which are bonded via carbon-carbon single bonds, results in a noticeable increase in the hydrolysis stability and thus also in the antibacterial action of axapenemcarboxylic acids.
结构式为##STR1##的化合物及其药学上可接受的盐、酯和酰胺衍生物,其中R.sup.1和R.sup.2分别表示氢或药学上可接受的基团,该基团具有1至10个碳原子,并通过碳-碳单键连接到分子的其余部分,而R.sup.3、R.sup.4和R.sup.5分别表示药学上可接受的基团,该基团具有1至10个碳原子,并通过碳-碳单键连接到分子的其余部分,这些化合物是有用的抗生素。通过三个通过碳-碳单键连接的基团R.sup.3、R.sup.4和R.sup.5的三次取代,可显着增加羟解稳定性,从而增强阿萨培南羧酸的抗菌作用。